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Dauvilliers et al1 negative study has challenged our discovery that human 
cerebrospinal fluid (CSF) enhances the activation of GABAA receptors 
(GABAA-R) 2. A companion letter3 and data in Figure 1 demonstrate flaws in 
Dauvilliers' experimental design and underscore that our data are robust and 
reproducible, essential prerequisites for guiding successful clinical trials4. 
 
 GABAA-R enhancement occurs when a positive allosteric modulator (PAM) 
increases agonist apparent affinity. This effect depends strongly on the effective 
agonist concentration (EC) used. To demonstrate this, we measured the effect of 
a single subject’s CSF on GABAA-Rs activated by a range of ECs (EC10-95, 
Figure 1A) using established methods2. CSF enhanced GABAA-Rs at low ECs 
and this effect disappeared as EC increased (Figure 1B). Thus, if the EC is too 
high, a powerful PAM will appear to have little or no effect. For this reason, we 
always ensure our agonist concentration activates a response that is 10% of the 
maximum in every cell before testing a CSF sample (EC10). To emphasize the 
utility of our method, we determined enhancement for 32 additional subjects in 2 
separate laboratories, one at Emory, the other at the University of Queensland2,5  
(Figure 1C). The correlation (r = 0.79) between the two replicates confirmed our 
rigorous methods generate reproducible data.  
 
Dauvilliers et al. failed to account for cell-cell EC variability in their CSF assays, 
on average using an EC94, not EC50 as reported. Under these conditions, a CSF 
that enhanced EC10 by 100% would only yield a 4% enhancement and would 
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require more than 50 replicates to be statistically significant. Dauvilliers’ 
concentration-response data demonstrate that low ECs activate plateaued 
responses whereas high ECs activate desensitizing responses that decrease 
rapidly despite the presence of GABA. Desensitization is strongly dependent on 
EC (Figure 1D) therefore the size of the decrease can be used to estimate EC. 
Dauvilliers’ α1- and α2-data show a mean decrease of 11.6 ± 1.2%, n=15 and 
15.9 ± 2.2%, n=6 respectively. Therefore, extrapolating from our concentration-
desensitization relationships in Figure 1D, we find the EC in Dauvilliers’ CSF 
assays was on average an EC94 and thus, too high to be useful:  
 
Finally, desensitization can reduce peak currents, an effect increased by PAMs 
(see Figure 1A), resulting in CSF-mediated inhibition. This effect further 
undermines the reliability of Dauvilliers’ data and we conclude their study 
does not establish an absence of effect, but instead suffers from flawed 
experimental design.  
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Figure 1 
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Figure 1. A. Example trace of currents recorded from α1β2γ2 GABAARs in 
response to 10- 300µM GABA ± 50% CSF. Dotted lines and arrows mark the 
degree/direction of modulation. Notice that low ECs result in enhancement while 
high ECs result in desensitization and inhibition. Scale bar: 5sec, 1000pA. B.  
Average enhancement (%) measured from peak currents (I): (IGABA+CSF – 
IGABA)/(IGABA)*100 for each GABA concentration shown in Figure A. (In Figure 1A, 
notice how enhancement is nearly zero at 30µM and negative beyond that as 
peaks desensitize, making measurements of enhancement unreliable. C. 
Enhancement comparison of 32 CSFs in 2 populations of receptors: 
enhancement of α2β2 receptors determined using planar patch clamp 
electrophysiology at the University of Queensland (Lynch Lab) and enhancement 
of α1β2γ2 receptors determined using single electrode patch clamp 
electrophysiology at Emory University (Jenkins Lab). The line represents the line 
of identity. D. Average desensitization of peak currents from α1β2γ2 (●) and 
α2β2γ2 (◊) receptors, calculated as the difference of peak amplitude to the 
amplitude at the end of each GABA exposure. Linear regressions to calculate 
desensitization (d%) as a function of log[GABA] for each receptor were: α1: 
d%=8.67*log[GABA]-11.53 and α2: d%=18.12*log[GABA]-16.68. Effective 
concentrations for each GABA concentration could be back calculated using 
Hill=1.36 (α1) and 1.53 (α2) and EC50= 60µM (α1) and 8.8µM (α2) and the Hill 
equation: I/Imax = [GABA]nH/([GABA]nH + EC50nH). Trace inset of a 2 sec exposure 
of saturating (300µM) GABA to α2β2γ2 receptors with dotted lines and arrow 
indicating the degree of desensitization. Scale bar: 1sec, 1000pA. n=24 cells 
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(α1), n=35 cells (α2).  Where not shown, the error bars are smaller than the 
symbol.  
